SICOR and BioGeneriX in joint recombinant protein development programme
SICOR, of California, has signed a license, development and marketing agreement with German biopharmaceutical company BioGeneriX, focused on the development of generic biopharmaceuticals.
SICOR, of California, has signed a license, development and marketing agreement with German biopharmaceutical company BioGeneriX, focused on the development of generic biopharmaceuticals.
SICOR and BioGeneriX will jointly develop a recombinant protein pharmaceutical product, which would be manufactured and produced by SICOR and marketed in Europe by BioGeneriX's parent company, ratiopharm, following regulatory approval.
SICOR would have the right to use the clinical data generated by BioGeneriX for the European regulatory filing to obtain marketing approval in the US and certain other countries. BioGeneriX will receive a royalty on SICOR sales in North and Central America.
'Our goal is to produce and market cost-effective biopharmaceutical products to benefit patients around the world,' said Marvin Samson, SICOR president and chief executive officer. 'This collaboration provides access to European markets through the BioGeneriX clinical development programme and ratiopharm's sales force while simultaneously giving SICOR the potential to expedite its entry into North American biopharmaceutical markets.'